Does Systemic Immune Inflammation Index Predicts Survival In Diffuse Large B Cell Lymphoma Patients?

Merih Reis Aras; Hacer Berna Afacan Öztürk; Fatma Yılmaz; Ümit Yavuz Malkan; Ahmet Kürşad Güneş; Murat Albayrak

Makale detayları

Does Systemic Immune Inflammation Index Predicts Survival In Diffuse Large B Cell Lymphoma Patients?

Yazarlar:

Merih Reis Aras | Hacer Berna Afacan Öztürk | Fatma Yılmaz | Ümit Yavuz Malkan | Ahmet Kürşad Güneş | Murat Albayrak

Yayıncı:

Hitit University

Ana Başlıklar:

Klinik Tıp Bilimleri

Dergi:

Hitit Medical Journal Vol.5 Issue 3, pp.170-174

Belge Tipi:

Makale

Yayın Tarihi:

10/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001300835

pISSN:

2687-4717

Anahtar kelimeler:

Özet:

 Objective: The systemic immune inflammation index has been considered a novel prognostic biomarker in several malignant tumors. The aim of the current study was to determine the association between the systemic immune inflammation index and prognosis of patients with Diffuse Large B Cell Lymphoma. Material and Method: The study included 101 patients diagnosed diffuse large B cell lymphoma. Receiver operating characteristic ROC curve analysis was used to determine the optimal cut-off value of the systemic immune inflammation index for predicting survival. Results: The results of ROC curve analysis showed a cut-off value for the systemic immune inflammation index of 500. No statistically significant difference was determined between the groups with systemic immune inflammation index  500 and 500 groups in respect of overall-survival and progression-free survival. The mortality risk was determined to be significantly higher in patients with systemic immune inflammation index  500 p:0.017. There was no significant relationship between the systemic immune inflammation index values and lactat dehydrogenase, age, R-IPI risk groups,ECOG performance status, and disease stage. Conclusion: The results of this study demonstrated that there is no association between the systemic immune inflammation index and survival in patients with diffuse large B cell lymphoma. Larger prospective studies are needed to investigate the association between the systemic immune inflammation index and Diffuse Large B Cell Lymphoma.

 Objective: The systemic immune inflammation index has been considered a novel prognostic biomarker in several malignant tumors. The aim of the current study was to determine the association between the systemic immune inflammation index and prognosis of patients with Diffuse Large B Cell Lymphoma. Material and Method: The study included 101 patients diagnosed diffuse large B cell lymphoma. Receiver operating characteristic ROC curve analysis was used to determine the optimal cut-off value of the systemic immune inflammation index for predicting survival. Results: The results of ROC curve analysis showed a cut-off value for the systemic immune inflammation index of 500. No statistically significant difference was determined between the groups with systemic immune inflammation index  500 and 500 groups in respect of overall-survival and progression-free survival. The mortality risk was determined to be significantly higher in patients with systemic immune inflammation index  500 p:0.017. There was no significant relationship between the systemic immune inflammation index values and lactat dehydrogenase, age, R-IPI risk groups,ECOG performance status, and disease stage. Conclusion: The results of this study demonstrated that there is no association between the systemic immune inflammation index and survival in patients with diffuse large B cell lymphoma. Larger prospective studies are needed to investigate the association between the systemic immune inflammation index and Diffuse Large B Cell Lymphoma.

 Objective: The systemic immune inflammation index has been considered a novel prognostic biomarker in several malignant tumors. The aim of the current study was to determine the association between the systemic immune inflammation index and prognosis of patients with Diffuse Large B Cell Lymphoma. Material and Method: The study included 101 patients diagnosed diffuse large B cell lymphoma. Receiver operating characteristic ROC curve analysis was used to determine the optimal cut-off value of the systemic immune inflammation index for predicting survival. Results: The results of ROC curve analysis showed a cut-off value for the systemic immune inflammation index of 500. No statistically significant difference was determined between the groups with systemic immune inflammation index  500 and 500 groups in respect of overall-survival and progression-free survival. The mortality risk was determined to be significantly higher in patients with systemic immune inflammation index  500 p:0.017. There was no significant relationship between the systemic immune inflammation index values and lactat dehydrogenase, age, R-IPI risk groups,ECOG performance status, and disease stage. Conclusion: The results of this study demonstrated that there is no association between the systemic immune inflammation index and survival in patients with diffuse large B cell lymphoma. Larger prospective studies are needed to investigate the association between the systemic immune inflammation index and Diffuse Large B Cell Lymphoma.

 Amaç: Sistemik immün inflamasyon indeksi, birçok malign tümörde kullanılan yeni bir prognostik biyobelirteçtir. Bu çalışmanın amacı, Diffüz Büyük B Hücreli Lenfoma hastalarında sistemik immün inflamasyon indeksi ile prognoz arasındaki ilişkiyi belirlemektir. Gereç ve Yöntem: Çalışmaya Diffüz Büyük B Hücreli Lenfoma tanılı 101 hasta dahil edildi. Sağkalımı öngören optimum sistemik immün inflamasyon indeksi kesme değerini saptamak için receiver operating charecteristic curve analizi kullanıldı. Bulgular: Receiver operating charecteristic curve analizi ile sistemik immün inflamasyon indeksi kesme değeri 500 saptandı. Sistemik immün inflamasyon indeksi  500 ve sistemik immün inflamasyon indeksi 500 grupları arasında progresyonsuz sağkalım ve genel sağkalım açısından istatistiksel olarak anlamlı fark yoktu. Ancak sistemik immün inflamasyon indeksi  500 olan hastalarda mortalite riski anlamlı olarak yüksekti p:0,017. Sistemik immün inflamasyon indeksi ile laktat dehidrogenaz, yaş, R-IPI risk grupları, ECOG performans durumu ve hastalık evresi arasında anlamlı bir ilişki yoktu. Sonuç: Çalışmamızın sonuçları, Diffüz Büyük B Hücreli Lenfoma hastalarında sistemik immün inflamasyon indeksi ile sağkalım arasında bir ilişki olmadığını göstermiştir. Sistemik immün inflamasyon indeksi ve DBBHL arasındaki ilişkiyi araştırmak için daha büyük prospektif çalışmalara ihtiyaç vardır.

Makale detayları

Does Systemic Immune Inflammation Index Predicts Survival In Diffuse Large B Cell Lymphoma Patients?

Yazarlar:

Merih Reis Aras | Hacer Berna Afacan Öztürk | Fatma Yılmaz | Ümit Yavuz Malkan | Ahmet Kürşad Güneş | Murat Albayrak

Yayıncı:

Hitit University

Ana Başlıklar:

Klinik Tıp Bilimleri

Dergi:

Hitit Medical Journal Vol.5 Issue 3, pp.170-174

Belge Tipi:

Makale

Yayın Tarihi:

10/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001300835

pISSN:

2687-4717

Diffuse large B cell lymphoma

systemic immun inflamation index

platelet

neutrophil

lymphocyte

survivalDiffüz büyük B hücreli lenfoma

Lenfosit

Nötrofil

Platelet

Sağkalım

Sistemik immün inflamasyon inde

Sayı

Makale detayları

Yazarlar: Merih Reis Aras | Hacer Berna Afacan Öztürk | Fatma Yılmaz | Ümit Yavuz Malkan | Ahmet Kürşad Güneş | Murat Albayrak

Yayıncı: Hitit University

Ana Başlıklar: Klinik Tıp Bilimleri

Dergi: Hitit Medical Journal Vol.5 Issue 3, pp.170-174

Belge Tipi: Makale

Yayın Tarihi: 10/2023

Belge Dili: İngilizce

Document ID (Org No.): 2001300835

pISSN: 2687-4717

Sayı

Yazarlar:

Merih Reis Aras | Hacer Berna Afacan Öztürk | Fatma Yılmaz | Ümit Yavuz Malkan | Ahmet Kürşad Güneş | Murat Albayrak

Yayıncı:

Hitit University

Ana Başlıklar:

Klinik Tıp Bilimleri

Dergi:

Hitit Medical Journal Vol.5 Issue 3, pp.170-174

Belge Tipi:

Makale

Yayın Tarihi:

10/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001300835

pISSN:

2687-4717